Results 231 to 240 of about 58,392 (301)

Chronic Prostate Cancer-Related Symptoms and Toxicities Following Stereotactic Body Radiation Therapy: Implications for Future Radionuclide Therapy. [PDF]

Cureus
Kallam D, Gaudian K, Collins R, Zwart Z, Koh MJ, Danner MT, Zwart AL, Kumar D, Simeng S, Gudenkauf L, Fallick M, Esposito G, Gonzalez B, Collins S.   +13 more
europepmc   +1 more source

Considerations for Establishing Peptide Receptor Radionuclide Therapy: A Nationally Coordinated, Collaborative, and Equitable Service for New Zealand. [PDF]

World J Nucl Med
Steyn R, Henderson A, Wells K, Mead T, Rennie Y, Hull A, Meredith L, Sullivan M, Simmers S, Davidson J, Hauraki T, Damianovich D, Boyle V, Lawrence B.   +13 more
europepmc   +1 more source

Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy. [PDF]

Front Oncol
Cengiz TB, Kulkarni R, Corbett V, Ghesani NV, Wolin E, Ghesani MV.   +5 more
europepmc   +1 more source

Immune modulation following α and β^- radionuclide therapy targeting fibroblast activation protein-α in a preclinical tumor model. [PDF]

Oncoimmunology
Ceuppens H, De Ridder K, Ertveldt T, Zeven K, De Mey W, Pombo Antunes AR, Navarro L, Dumauthioz N, Lahoutte T, Debacker JM, Devoogdt N, Keyaerts M, D'Huyvetter M, Goyvaerts C, Breckpot K.   +14 more
europepmc   +1 more source

Fibrosis markers as prognostic markers of decline in kidney function in patients with neuroendocrine neoplasms undergoing peptide receptor radionuclide therapy. [PDF]

Front Endocrinol (Lausanne)
Stemann Lau T, Bossen L, Rasmussen DGK, Genovese F, Karsdal M, Arveschoug AK, Grønbæk H, Dam G.   +7 more
europepmc   +1 more source

Direct Labeling of Gold Nanoparticles with Iodine-131 for Tumor Radionuclide Therapy. [PDF]

Int J Nanomedicine
Zhu M, Zhao L, Lu X.
europepmc   +1 more source

Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients receiving peptide receptor radionuclide therapy. [PDF]

Front Endocrinol (Lausanne)
Mathew A, Kersting D, Fendler WP, Braegelmann J, Fuhrer D, Lahner H.   +5 more
europepmc   +1 more source

Self-illuminating liposome-derived <i>in situ</i> triggerable photodynamic therapy combining radionuclide therapy for synergistic treatment of lung cancer. [PDF]

Acta Pharm Sin B
Yuan C, Jin T, Lei H, Liu J, Pu W, Zhang Y, Li C, Huang D, Zhang J, Guo J.   +9 more
europepmc   +1 more source

Multicycle Dosimetric Behavior and Dose-Effect Relationships in [¹⁷⁷Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy. [PDF]

J Nucl Med
Kayal G, Roseland ME, Wang C, Fitzpatrick K, Mirando D, Suresh K, Wong KK, Dewaraja YK.   +7 more
europepmc   +1 more source